Foghorn therapeutics announces chief scientific officer succession

Cambridge, mass., jan. 10, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced steven bellon, ph.d., currently senior vice president of drug discovery, is promoted to chief scientific officer, effective today, january 10, 2022. carl decicco, ph.d., is retiring from his role as chief scientific officer at foghorn.
FHTX Ratings Summary
FHTX Quant Ranking